Latest Conference Articles

Watch Dr. Debu Tripathy, from The University of Texas MD Anderson Cancer Center, discuss circulating tumor DNA during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Watch Dr. Susan Domchek, from Penn Medicine, discuss genetic testing during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Watch Dr. William J Gradishar, Dr. Kevin Kalinsky and Kelly Thomas answer questions about hormone receptor-positive and triple-negative breast cancer treatment options during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Watch Dr. Kevin Kalisnky, from Winship Cancer Institute of Emory University, discuss treatment for triple-negative disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Watch Dr. William J. Gradishar, from Northwestern University, discuss the management of hormone receptor-positive disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Watch Isabel Octaviano, from Miami Cancer Institute, Baptist Health South Florida, discuss the nursing perspective to clinical trials during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Watch Dr. Reshma Mahtani, from Miami Cancer Institute, Baptist Health South Florida, discuss clinical trial myths during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Watch Dr. Anne O'Dea, from University of Kansas Medical Center, discuss targeting ESR1 mutations during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Long-term follow-up of Nubeqa for nonmetastatic castration-resistant prostate cancer showed that the drug was safe and effective in treating this patient population.

After a patient receives a kidney cancer diagnosis, there are some important conversations to have with their health care team.

An expert explains what patients with low-grade prostate cancer can expect when undergoing genomic testing — and why the procedure is important.

Important data may encourage gender-specific treatment making decisions for patients with bladder cancer.

A clinical trial is currently enrolling patients who are experiencing hand-foot skin reaction as a result of kidney cancer treatment.

The addition of Tecentriq to platinum-based chemotherapy/gemcitabine did not boost outcomes in patients with metastatic bladder cancer, according to results from the IMvigor 140 trial.

The addition of Cabometyx to Opdivo and Yervoy improved outcomes for patients with advanced kidney cancer, according to recent research.

Researchers identified several biomarkers that may indicate how a patient responds to Padcev, a type of antibody drug conjugate for patients with urothelial carcinoma, a type of bladder cancer.

The combination demonstrated survival benefit in patients with metastatic hormone-sensitive prostate cancer, regardless of risk or volume of disease.

The administration of Pluvicto within six months of radium-223 treatment proved to be safe and efficacious in patients with metastatic castration-resistant prostate cancer, research showed.

Patients treated with Nubeqa were less likely to develop disease metastasis or discontinue treatment 6 to 18 months after ARI course start compared to Xtandi or Erleada, according to data presented at ASCO GU.

Patients with pretreated metastatic colorectal cancer had better outcomes when Avastin was added to their Lonsurf treatment in the third line setting.

Patients with pancreatic cancer who underwent stereotactic body radiation tended to have fewer side effects and treatment sessions compared to those who had intensity-modulated radiation therapy.

Patients who underwent minimally invasive treatment tended to have better quality-of-life outcomes than those who had a full esophagus removal, though there were risk factors for long-term outcomes that should be considered.

Patients with advanced HCC who progressed after treatment with immunotherapy may have a survival benefit when treated with second-line Lenvima.

Patients with gastric cancer who quit smoking and/or drinking after undergoing a gastrectomy tended to have a decreased risk of depression, research showed.

Zolbetuximab plus mFOLFOX6 lengthened the time to progression for patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma.

Patients with HER2-low gastric cancer tended to have distinct characteristics compared to those with HER2-negative or -positive disease, warranting more research into this group, research found.

Watch Dr. Aaron Gerds and Dr. Andrew Kuykendall answer questions about myelofibrosis during the CURE Educated Patient MPN Summit.

Watch Dr. Andrew Kuykendall, from the Mofitt Cancer Center, discuss second-line treatments and beyond for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.